New 'Living Drug' trial targets deadly cancer mutation

This early-stage study is testing a new type of personalized cell therapy for people with advanced colorectal, pancreatic, or non-small cell lung cancer. The therapy involves collecting a patient's own immune cells, genetically modifying them to target a specific cancer-causing mutation called KRAS G12V, and then infusing them back into the patient. The main goals are to see if this approach is safe and to get an early look at whether it can help control these difficult-to-treat cancers.